RNA‐seq of comprehensively examine variations in MHCC-97H cells treated with various doses of lenvatinib at the transcriptomic level.

To determine the drug target of lenvatinib, RNAseq was used to evaluate the transcriptome differences between lenvatinib-treated MHCC-97H cells and their parental counterparts.Results show that SERPINE1 may be direct target of lenvatinib, and AKR1C1 have potential prognostic significance in the prediction of LR(lenvatinib-resistant) in HCC. AKR1C1 could be a promising therapeutic target for patients with LR-type liver cancer. MHCC-97H cells treated with 40, 60, 80, and 100 μM lenvatinib, and RNAseq was used to evaluate the transcriptome differences between lenvatinib-treated MHCC-97H cells and their parental counterparts.For more information, please consult [e-mail]

为明确仑伐替尼（lenvatinib）的药物靶点，本研究采用RNA测序（RNAseq）分析仑伐替尼处理的MHCC-97H细胞与其亲本细胞的转录组差异。结果显示，SERPINE1可能为仑伐替尼的直接作用靶点，AKR1C1在预测肝细胞癌（HCC）仑伐替尼耐药（LR）患者的预后方面具有潜在价值，或可成为仑伐替尼耐药型肝癌患者的潜在治疗靶点。本研究设置40、60、80、100 μM四个浓度梯度的仑伐替尼处理MHCC-97H细胞，并通过RNA测序分析不同浓度仑伐替尼处理组细胞与亲本细胞的转录组差异。如需获取更多信息，请联系邮箱[e-mail]